Literature DB >> 15652923

First derivation in Spain of human embryonic stem cell lines: use of long-term cryopreserved embryos and animal-free conditions.

Carlos Simón1, Carmen Escobedo, Diana Valbuena, Olga Genbacev, Amparo Galan, Ana Krtolica, Angeles Asensi, Eva Sánchez, Juan Esplugues, Susan Fisher, Antonio Pellicer.   

Abstract

The first two human embryonic stem cell lines (VAL-1 and VAL-2) have been derived in Spain with long-term cryopreserved embryos under animal-free conditions. In the first series, 40 human embryos that had been cryopreserved at day 2 of development were thawed after >5 years. A derivation efficiency of 5% per frozen embryo or 12.5% per blastocyst was obtained.

Entities:  

Mesh:

Year:  2005        PMID: 15652923     DOI: 10.1016/j.fertnstert.2004.09.004

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  13 in total

1.  SNL fibroblast feeder layers support derivation and maintenance of human induced pluripotent stem cells.

Authors:  Chuanying Pan; Amy Hicks; Xuan Guan; Hong Chen; Colin E Bishop
Journal:  J Genet Genomics       Date:  2010-04       Impact factor: 4.275

2.  Derivation of Man-1 and Man-2 research grade human embryonic stem cell lines.

Authors:  Maria V Camarasa; Robbie W Kerr; Sharon F Sneddon; Nicola Bates; Lisa Shaw; Rachel A Oldershaw; Fiona Small; Melissa A Baxter; Tristan R Mckay; Daniel R Brison; Susan J Kimber
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-02-23       Impact factor: 2.416

3.  Establishment and characterization of human embryonic stem cell lines, Turkey perspectives.

Authors:  Zafer Nihat Candan; Semra Kahraman
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-03-27       Impact factor: 2.416

Review 4.  Human embryonic stem cells: potential tool for achieving immunotolerance?

Authors:  Pablo Menendez; Clara Bueno; Lisheng Wang; Mickie Bhatia
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

5.  Derivation, characterization, differentiation, and registration of seven human embryonic stem cell lines (VAL-3, -4, -5, -6M, -7, -8, and -9) on human feeder.

Authors:  Cristobal Aguilar-Gallardo; Maria Poo; Eva Gomez; Amparo Galan; Eva Sanchez; Ana Marques-Mari; Veronica Ruiz; Jose Medrano; Marcia Riboldi; Diana Valbuena; Carlos Simon
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-02-26       Impact factor: 2.416

6.  Placental-derived mesenchyme influences chorionic gonadotropin and progesterone secretion of human embryonic stem cell-derived trophoblasts.

Authors:  Maria Giakoumopoulos; Leah M Siegfried; Svetlana V Dambaeva; Mark A Garthwaite; M Clay Glennon; Thaddeus G Golos
Journal:  Reprod Sci       Date:  2010-07-02       Impact factor: 3.060

7.  Triploid and diploid embryonic stem cell lines derived from tripronuclear human zygotes.

Authors:  Xinjie Chen; Yumei Luo; Yong Fan; Lei Yue; Xueshi Wu; Yaoyong Chen; Xiaofang Sun
Journal:  J Assist Reprod Genet       Date:  2012-04-12       Impact factor: 3.412

8.  Generation of Mouse STO Feeder Cell Lines That Confer Resistance to Several Types of Selective Drugs.

Authors:  Issei Saitoh; Masahiro Sato; Yoko Iwase; Emi Inada; Toshiki Nomura; Eri Akasaka; Youichi Yamasaki; Hirofumi Noguchi
Journal:  Cell Med       Date:  2012-05-08

9.  Derivation of xeno-free and GMP-grade human embryonic stem cells--platforms for future clinical applications.

Authors:  Shelly E Tannenbaum; Tikva Tako Turetsky; Orna Singer; Einat Aizenman; Sophie Kirshberg; Nili Ilouz; Yaniv Gil; Yael Berman-Zaken; Temima Schnitzer Perlman; Nitshia Geva; Ora Levy; Daniel Arbell; Alex Simon; Assaf Ben-Meir; Yoel Shufaro; Neri Laufer; Benjamin E Reubinoff
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

10.  Defining the genomic signature of totipotency and pluripotency during early human development.

Authors:  Amparo Galan; Patricia Diaz-Gimeno; Maria Eugenia Poo; Diana Valbuena; Eva Sanchez; Veronica Ruiz; Joaquin Dopazo; David Montaner; Ana Conesa; Carlos Simon
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.